Institut Pasteur-ko ikertzaileekin lankidetzan egindako argitalpenak (1)

2016

  1. Efficacy of the Janus kinase 1/2 inhibitor ruxolitinib in the treatment of vasculopathy associated with TMEM173-activating mutations in 3 children

    Journal of Allergy and Clinical Immunology, Vol. 138, Núm. 6, pp. 1752-1755